Diabetes Care:糖尿病筛查--HbA1c筛查更有效

2015-04-13 崔倩译 MedSci原创

目的:为了提供在加拿大第一个以人群为基础的估计糖尿病前期和未确诊的2型糖尿病患者的患病率。 研究设计和方法:我们结合了加拿大卫生措施调查的两种空腹样品,这仅限于≥20岁非妊娠成人(N =3494)。未确诊的糖尿病被定义为不具有自我报告的2型糖尿病,但能够满足加拿大规范(即,空腹血糖[FGP]水平≥7.0毫摩尔/升或血红蛋白A1c[HbA1c]≥6.5%[≥48毫摩尔/摩尔])。前期糖尿病被定义为

目的:评估未确诊的2型糖尿病和前期糖尿病的患病率。

研究设计和方法:我们结合了加拿大卫生措施调查的两种空腹样品,这仅限于≥20岁非妊娠成人(N =3494)。未确诊的糖尿病被定义为不具有自我报告的2型糖尿病,但能够满足加拿大规范(即,空腹血糖[FGP]水平≥7.0毫摩尔/升或血红蛋白A1c[HbA1c]≥6.5%[≥48毫摩尔/摩尔])。前期糖尿病被定义为FPG水平≥6.1且<7.0毫摩尔/升或血红蛋白水平≥6.0%且<6.5%(≥42和<48毫摩尔/摩尔)。所有的估计使用抽样调查的权重进行加权。用bootstrap方法计算Cls。

结果:根据FPG水平,未确诊的2型糖尿病在加拿大成年人的患病率为1.13%(95%Cl 0.79,1.62),组成了2型糖尿病患总病率的约20%(5.62[95%Cl 4.52,6.95])。与FPG水平相比,使用血红蛋白水平为标准的未确诊患病率更高(3.09%[95%Cl 1.97,4.81)],构成了糖尿病病例总数的约41%(7.55[95%Cl 5.98,9.49] )。糖化血红蛋白-唯一标准导致糖尿病前期总体患病率增加了三倍,女性中增加了六倍(FPG 2.22%,糖化血红蛋白13.31%)。用FPG筛选识别年龄大的未确诊的患者的情况下,平均年龄为58.7岁(95%Cl  59.9,63.4)。同样,使用糖化血红蛋白确定年轻个体前期糖尿病,与FGP水平相比有降低的BMI和腰围。

结论:在这项首次具有全国代表性的样本的生物措施研究中,我们发现,与FPG水平比较,使用HbA1c筛查未确诊的2型糖尿病和前期糖尿病的患病率明显较高。

原始出处

Rosella LC1, Lebenbaum M2, Fitzpatrick T2, Zuk A3, Booth GL4.The Prevalence of Undiagnosed and Prediabetes Diabetes in Canada (2007-2011) According to Fasting Plasma Glucose and HbA1c Screening Criteria.Diabetes Care. 2015 Apr 7.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1637069, encodeId=1954163e0695f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Nov 02 08:59:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759538, encodeId=0f9b1e595383e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Jun 21 03:59:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901278, encodeId=9acd19012e8ce, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Jan 08 15:59:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015897, encodeId=7bc7201589ebc, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Dec 18 13:59:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27074, encodeId=00f42e07433, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:37:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21110, encodeId=c54b21110f9, content=总结得不错,理论支持多点儿, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac31621431, createdName=Handyuan, createdTime=Mon Apr 13 15:20:00 CST 2015, time=2015-04-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1637069, encodeId=1954163e0695f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Nov 02 08:59:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759538, encodeId=0f9b1e595383e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Jun 21 03:59:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901278, encodeId=9acd19012e8ce, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Jan 08 15:59:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015897, encodeId=7bc7201589ebc, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Dec 18 13:59:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27074, encodeId=00f42e07433, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:37:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21110, encodeId=c54b21110f9, content=总结得不错,理论支持多点儿, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac31621431, createdName=Handyuan, createdTime=Mon Apr 13 15:20:00 CST 2015, time=2015-04-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1637069, encodeId=1954163e0695f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Nov 02 08:59:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759538, encodeId=0f9b1e595383e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Jun 21 03:59:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901278, encodeId=9acd19012e8ce, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Jan 08 15:59:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015897, encodeId=7bc7201589ebc, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Dec 18 13:59:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27074, encodeId=00f42e07433, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:37:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21110, encodeId=c54b21110f9, content=总结得不错,理论支持多点儿, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac31621431, createdName=Handyuan, createdTime=Mon Apr 13 15:20:00 CST 2015, time=2015-04-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1637069, encodeId=1954163e0695f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Nov 02 08:59:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759538, encodeId=0f9b1e595383e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Jun 21 03:59:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901278, encodeId=9acd19012e8ce, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Jan 08 15:59:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015897, encodeId=7bc7201589ebc, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Dec 18 13:59:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27074, encodeId=00f42e07433, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:37:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21110, encodeId=c54b21110f9, content=总结得不错,理论支持多点儿, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac31621431, createdName=Handyuan, createdTime=Mon Apr 13 15:20:00 CST 2015, time=2015-04-13, status=1, ipAttribution=)]
    2015-12-18 Smile2680
  5. [GetPortalCommentsPageByObjectIdResponse(id=1637069, encodeId=1954163e0695f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Nov 02 08:59:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759538, encodeId=0f9b1e595383e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Jun 21 03:59:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901278, encodeId=9acd19012e8ce, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Jan 08 15:59:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015897, encodeId=7bc7201589ebc, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Dec 18 13:59:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27074, encodeId=00f42e07433, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:37:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21110, encodeId=c54b21110f9, content=总结得不错,理论支持多点儿, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac31621431, createdName=Handyuan, createdTime=Mon Apr 13 15:20:00 CST 2015, time=2015-04-13, status=1, ipAttribution=)]
    2015-06-11 ljjj1053

    好好学习一下

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1637069, encodeId=1954163e0695f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Nov 02 08:59:00 CST 2015, time=2015-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759538, encodeId=0f9b1e595383e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Jun 21 03:59:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901278, encodeId=9acd19012e8ce, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Jan 08 15:59:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015897, encodeId=7bc7201589ebc, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Dec 18 13:59:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27074, encodeId=00f42e07433, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Thu Jun 11 18:37:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21110, encodeId=c54b21110f9, content=总结得不错,理论支持多点儿, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac31621431, createdName=Handyuan, createdTime=Mon Apr 13 15:20:00 CST 2015, time=2015-04-13, status=1, ipAttribution=)]
    2015-04-13 Handyuan

    总结得不错,理论支持多点儿

    0

相关资讯

Nature:肥胖相关受体具有独特结构

发表在国际著名杂志Nature上的一篇研究论文中,来自日本理化研究所等处的研究人员通过利用名为SPring-8的同步加速器阐明了脂连素两种受体的结构,脂连素是一种和肥胖及糖尿病直接相关的蛋白质,研究人员希望本文研究可以为后期设计新型药物靶向作用AdipoR1和AdipoR2受体来降低和糖尿病相关的早期死亡率提供新的思路。 脂连素是一种由脂肪细胞分泌产生的激素蛋白,其被认为可以参与葡萄糖及脂肪

Diabetes Care:达帕格列净对2型糖尿病心血管风险因素的影响

目的:评估达帕格列净(dapagliflozin)的疗效和安全性,选择性钠 - 葡萄糖协同转运蛋白2的抑制剂,与2型糖尿病(T2D)患者的安慰剂相比,可以记录预先存在的心血管疾病(CVD),以及高血压病史。 研究设计与方法:患者(N=922)被随机分配接受10毫克的达帕格列净或安慰剂的双盲试验24周,之后是28周的延长期。在接受胰岛素的患者中,胰岛素的剂量随机化减少了25%。患者按年龄,胰岛素

JCEM:孕期糖尿病对其后代代谢的影响

孕妇孕期糖尿病会增加其及后代远期发生2型糖尿病(T2DM)和其他代谢综合征发病风险,而T2DM发病与肠促胰岛素、胰高血糖素样肽-1(GLP-1)、葡萄糖依赖性促胰岛素多肽(GIP)、高血糖素症等有关。

Diabetes Care:不同种族老年糖尿病的患病率分析

目的:争论围绕着中老年人糖尿病患者相应的风险因素指标。我们评估了老年糖尿病患者满足不同指标的比例,集中于种族可能引起差异,并评估人口统计学和临床特征是否可以解释这种差距。 研究设计和方法:我们对5,018名年龄67-90岁的参与者(1574名被确诊为糖尿病,3444名没有被确诊为糖尿病)进行了横断面研究,这些参与者出席参观动脉粥样硬化风险5社区(ARIC)研究(2011-2013年)。风险因素

J Clin Periodontol:糖尿病前期以及控制良好的糖尿病与牙周病不存在相关关系

J Clin Periodontol:糖尿病前期以及控制良好的糖尿病与牙周病不存在相关关系关键词:糖尿病前期 糖尿病 牙周病 牙周炎 牙周附着丧失 无牙颌 高血糖 血糖紊乱 总所周知,糖尿病和牙周炎之间具有双向关系,牙周炎可以影响机体血糖控制,糖尿病又会影响机体的牙周状态。但是很少有研究关于糖尿病前期以及控制良好的糖尿病与牙周炎之间的关系。糖尿病前期是指介于糖尿病和正常血糖之间的一种状态,被认为是

Cell Metabol:靶向作用机体肠道免疫系统就可有效治疗糖尿病

治疗炎性肠病,比如克罗恩病的常见药物被证明可以降低肥胖小鼠的血糖水平,而近日刊登在国际杂志Cell Metabolism上的一篇研究报道中,来自多伦多综合研究所的研究人员则鉴别出,肠道免疫系统或许可以作为一种新型有效的靶点来帮助治疗人类肥胖。Dan Winer博士指出,相关研究结果非常重要,因为我们发现机体的免疫系统或许可以作为控制血糖的一个新型的调节子,这就为理解肠道免疫学机制来研究肥胖及其并发